New Zealand

New Zealand offers a world class track record in early phase trials, proof of concept trials and independent, clean and precise clinical data.

George Clinical In New Zealand

New Zealand requires only one ethics committee review per study – reducing clinical trial start-up timelines.

New Zealand has a respected reputation in medical research and is a place of innovation, honesty and entrepreneurial advancement. New Zealand offers a world class track record in early phase trials, proof of concept trials and independent, clean and precise clinical data.

New Zealand was the first country in the world to establish an electronic Population Health Index, a system that features a large database that contains approximately 20 years of health encounters and is now accompanied by an equally comprehensive Health Practitioner Index.

Sponsors who wish to conduct clinical trials in New Zealand must undergo specific procedures. The sponsor is required to make an application to Medsafe and Health and Disability Ethics Committees (HDECs), seeking permission to conduct a clinical trial in New Zealand and adhere to ongoing regulatory reporting procedures. Only one ethics committee review is required per study, which covers all sites. The process is simple and approximately takes 4-6 weeks from submission to full approval. Furthermore, Medsafe’s Standing Committee On Therapeutic Trials (SCOTT) approval process takes a maximum of 45 days (typically less). This process is not required for medical devices or new indications of New Zealand registered formulations; however, it is necessary for non-registered drug formulations.

New Zealand’s one ethical committee approval process does not require US FDA IDE filing prior to a study. As a result, sponsor’s wishing to develop medical devices for a rapid, cost effective means and gaining early proof of concept, should consider conducting their initial clinical trials in New Zealand.

What are the benefits of conducting clinical trials in New Zealand?

  • Trials in New Zealand are increasingly cost-effective as a result of pass through costs that are lower and considerable without sacrificing quality.
  • New Zealand consists of a diverse ethnic sub-population
  • New Zealand has a southern hemisphere advantage of reverse seasonality, boosting international recruitment

What are the prevalent diseases in New Zealand?

  1. Ischaemic Heart Disease
  2. Breast Cancer
  3. Lung Cancer
  4. Diabetes
  5. Chronic obstructive pulmonary disease
  6. Cerebrovascular disease


Our People in Australia / New Zealand are Experienced in

Cardiovascular 56%

Central Nervous System 42%

Medical Devices 26%

Endocrinology 42%

Oncology 47%

Respiratory 14%

Nephrology 50%



Level 14 PwC Tower, 188 Quay Street,
Auckland 1010
New Zealand
Phone: +61 2 8052 4300


Population 4.7 million
Official Language English is the predominant language spoken in New Zealand. However, the official languages of New Zealand are Maori and New Zealand Sign Language.
Hospital Records Language English
In-country services Clinical Operations
Regulatory Services
GDP – per capita (US $) $36,200
Health Expenditures 9.7% of GDP

Add George Clinical to your network